Crystal structure of the transthyretin--retinoic-acid complexZanotti, G., D'Acunto, M.R., Malpeli, G., Folli, C., Berni, R.
(1995) Eur J Biochem 234: 563-569
- PubMed: 8536704
- DOI: 10.1111/j.1432-1033.1995.563_b.x
- Primary Citation of Related Structures:
- PubMed Abstract:
- Crystallographic Studies on Complexes between Retinoids and Plasma Retinol-Binding Protein
Zanotti, G., Marcello, M., Malpeli, G., Folli, C., Sartori, G., Berni, R.
(1994) J Biol Chem 269: 29613
- Crystal Structure Determination at 2.3 Angstroms of Human Transthyretin-3',5'-Dibromo-2',4,4', 6-Tetra-Hydroxyaurone Complex
Ciszak, E., Cody, V., Luft, J.R.
(1992) Proc Natl Acad Sci U S A 89: 6644
- Mechanism of Molecular Recognition. Structural Aspects of 3,3'-Diiodo-L-Thyronine Binding to Human Serum Transthyretin
Wojtczak, A., Luft, J., Cody, V.
(1992) J Biol Chem 267: 353
- Protein-DNA and Protein-Hormone Interactions in Prealbumin: A Model of the Thyroid Hormone Nuclear Receptor?
Blake, C.C.F., Oatley, S.J.
(1977) Nature 268: 115
- Structure of Human Plasma Prealbumin at 2.5 Angstroms Resolution, a Preliminary Report on the Polypeptide Chain Conformation, Quaternary Structure and Thyroxine Binding
Blake, C.C.F., Geisow, M.J., Swan, I.D.A., Rerat, C., Rerat, B.
(1974) J Mol Biol 88: 1
Retinoids are quite insoluble and chemically unstable compounds in the aqueous medium, such that natural retinoids need to be bound to specific retinoid-binding proteins to be protected, solubilized and transported in body fluids. All-trans retinoic acid exhibits a relatively high affinity for thyroxine-binding transthyretin in vitro and this protein is a good candidate for the transport of retinoic acid administered as pharmacological or antitumor agent ...
Retinoids are quite insoluble and chemically unstable compounds in the aqueous medium, such that natural retinoids need to be bound to specific retinoid-binding proteins to be protected, solubilized and transported in body fluids. All-trans retinoic acid exhibits a relatively high affinity for thyroxine-binding transthyretin in vitro and this protein is a good candidate for the transport of retinoic acid administered as pharmacological or antitumor agent. To define structural features essential for the recognition by transthyretin of a ligand which is structurally unrelated to thyroxine, we have cocrystallized human transthyretin with retinoic acid and determined its structure at 0.18-nm resolution. The retinoid fits into the two chemically identical thyroxine-binding sites, which are located in the central channel that runs through the tetrameric transthyretin. The cyclohexene ring of the bound retinoid is innermost, occupying the same position of the phenolic ring of the bound 3,3'-diiodo-L-thyronine, whereas the carboxylate group, like the same group of the thyroid hormone, participates in an ionic interaction with the Lys15 side chain at the entrance of the channel. Despite the fact that transthyretin was cocrystallized with all-trans-retinoic acid, the isoprene chain of the bound retinoid has been found in a non-extended conformation. This feature, that allows the carboxylate to orient in a manner suitable for ion-pair association with the Lys15 side chain, is attributable to the conversion of all-trans-retinoic acid into cis-isomers or folded conformers. It is concluded that the presence, in an essentially hydrophobic molecular core of the appropriate size, of a negatively charged group at the correct position is a crucial requirement for ligand-transthyretin recognition. Whereas the binding of the ligand has no remarkable consequences for the protein structure, all-trans-retinoic acid undergoes structural changes such as to interact favorably with residues present in the thyroxine-binding sites, resembling roughly the natural ligand.
Department of Organic Chemistry, University of Padova, Italy.